Navigation Links
Dr. Peter C. Neligan, Author of 3rd Edition of Elsevier's Plastic Surgery Text, Available for Comment on the Contributions of Dr. Joseph Murray
Date:11/27/2012

PHILADELPHIA, Nov. 27, 2012 /PRNewswire/ -- In the wake of the passing of Nobel Prize winning surgeon Dr. Joseph Murray, who carried out the first successful kidney transplant in 1954, Dr. Peter C. Neligan, author of the definitive textbook of the discipline, Plastic Surgery, (3rd Ed., Elsevier, October 2012) is available to comment on Dr. Murray's legacy of innovation. Dr. Murray died on Monday in Boston at the age of 93.

"The history of Plastic Surgery is one of innovation in medicine, and Dr. Murray's contributions paved the way for developments that today continue in areas such as hand and face transplantation," says Dr. Neligan, author of five books, more than 50 book chapters and 170 peer-reviewed papers.

A professor of Plastic Surgery and Otolaryngology/Neck Surgery at the University of Washington Medical Center in Seattle, Dr. Neligan spent four years editing Plastic Surgery, working with the Elsevier team and with the volume editors. The 6-volume text is the first update in a decade, and includes 160 videos and online resources that bring the latest techniques to the practitioner's iPad or cell phone.

"Many people think of plastic surgery as a cosmetic practice, but Aesthetic Surgery fills only one of the six volumes in the Plastic Surgery text," Dr. Neligan says. "Plastic Surgeons are leading the way with new developments in stem cell therapy, tissue engineering, and inductive therapies; aesthetic surgical techniques and nonsurgical treatments; conjoined twin separation and other craniofacial surgery advances; microsurgical lymphatic reconstruction, super microsurgery, nerve transfers in hand surgery, functional prosthetics, and more."

Additional information about Dr. Neligan and Plastic Surgery is available at http://elsevierauthors.com/peterneligan.



'/>"/>
SOURCE Elsevier, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
4. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
5. Swiss, EMA, US Pharmacopoeia and World Health Organization Authorities to Provide an Update on Cool Chain Regulations
6. Auditors Complete Kansas Bioscience Authority Forensic Audits
7. Dietary Supplements Extensively Regulated, Say Authors of New Article
8. Fitzsimons Redevelopment Authority Names New President & CEO
9. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... This year has been one of the ... Patented Pearl’s Premium Ultra Low Maintenance Lawn Seed comes ... are coming out of record bad weather. Offering ... global concerns related to water, health, and climate change, ... to the standard, water-wasting, chemical-treated standard lawn. Many ...
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... , GAITHERSBURG, Md., Aug. 6 GenVec, Inc. (Nasdaq: ... quarter ended June 30, 2009. , , ... GenVec reported a net loss of $4.8 million ($0.05 per ... net loss of $6.6 million ($0.08 per share) in the comparable quarter ...
... , ROCKVILLE, Md., Aug. 6 Novavax, Inc. ... Frederick W. Driscoll as Vice President, Chief Financial Officer and ... Novavax,s President and Chief Executive Officer. , , ... President and Chief Executive Officer of Genelabs Technologies, Inc. ...
... , NEWTON, Mass., Aug. 6 Microfluidics International ... release second quarter 2009 financial results on Tuesday, August 11, ... , Michael C. Ferrara, President and Chief Executive Officer, ... Officer, will host a conference call and live audio webcast at ...
Cached Biology Technology:GenVec Reports Second Quarter 2009 Financial Results 2GenVec Reports Second Quarter 2009 Financial Results 3GenVec Reports Second Quarter 2009 Financial Results 4GenVec Reports Second Quarter 2009 Financial Results 5GenVec Reports Second Quarter 2009 Financial Results 6GenVec Reports Second Quarter 2009 Financial Results 7Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer 2Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009 2
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... at The University of Queensland could contribute to the ... virus and Dengue fever. Led by Associate ... School of Molecular and Microbial Sciences identified a novel ... belong. The team found all flaviviruses produced ...
... Harbor, N.Y. Much like cancer cells, plant cells ... milieu, in culture dishes, have highly unstable genomes. Changes ... cells cope with challenging culture conditions but inadvertently also ... of DNA that can jump around in the genome, ...
... can have genetic causes. Researchers at the Institute of ... correlation. The causes of what is known as irritable ... of the gastrointestinal tract, are considered unclear making ... which were published in the prestigious jour-nal " Human ...
Cached Biology News:UQ research targets West Nile virus and dengue fever 2CSHL researchers map changing epigenetic modifications that enable transposons to run amok 2Irritable bowel syndrome can have genetic causes 2
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, Canada) ... have collaborated to develop a fluorescence reader ... The DNAscope AT is based on BPIs ... automatically reads up to six ArrayTubes in ...
... Sciences provides a comprehensive kinase analysis ... substrate (PKS) peptide microarrays synthesized on ... kinase profiling, quantitative measurement of kinase ... This comprehensive service includes preparation of ...
Biology Products: